BioNTech (NASDAQ:BNTX) Trading Down 0.3% – What’s Next?

BioNTech SE (NASDAQ:BNTX) shares were down 0.3% during mid-day trading on Wednesday . The stock traded as low as $114.04 and last traded at $115.30. Approximately 65,586 shares were traded during trading, a decline of 92% from the average daily volume of 810,809 shares. The stock had previously closed at $115.59.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BNTX shares. UBS Group lifted their target price on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and increased their price objective for the company from $96.00 to $150.00 in a report on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and set a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. Finally, Bank of America raised their price target on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average target price of $138.67.

BioNTech Trading Down 0.6 %

The business’s 50-day moving average is $113.83 and its two-hundred day moving average is $99.12. The firm has a market cap of $27.55 billion, a P/E ratio of -54.90 and a beta of 0.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter last year, the company posted $0.73 EPS. BioNTech’s quarterly revenue was up 38.9% compared to the same quarter last year. As a group, analysts predict that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Several hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC raised its stake in BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after purchasing an additional 111 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares during the last quarter. Gallacher Capital Management LLC grew its holdings in shares of BioNTech by 12.1% during the 2nd quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company’s stock valued at $294,000 after purchasing an additional 395 shares during the last quarter. Finally, TD Asset Management Inc grew its holdings in shares of BioNTech by 6.1% during the 2nd quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after purchasing an additional 435 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.